Hong Kong (HSI) Biotech Industry Analysis
UpdatedJan 29, 2023
DataAggregated Company Financials
Companies39
- 7D3.4%
- 3M50.3%
- 1Y14.3%
- YTD10.4%
The Biotech industry is up 3.4% in the last week, with Innovent Biologics up 9.0%. This means that the industry has gained 14% over the past year. As for the next few years, earnings are expected to grow by 46% per annum.
Industry Valuation and Performance
Has the Hong Kong Biotech Industry valuation changed over the past few years?
| Date | Market Cap | Revenue | Earnings | PE | Absolute PE | PS |
|---|---|---|---|---|---|---|
| Sun, 29 Jan 2023 | HK$467.1b | HK$34.9b | -HK$35,242,741,407.00 | 31.3x | -13.3x | 13.4x |
| Tue, 27 Dec 2022 | HK$388.0b | HK$33.7b | -HK$33,948,658,471.00 | 23.1x | -11.4x | 11.5x |
| Thu, 24 Nov 2022 | HK$352.3b | HK$33.1b | -HK$33,281,981,877.00 | 21.2x | -10.6x | 10.7x |
| Sat, 22 Oct 2022 | HK$324.5b | HK$33.7b | -HK$32,118,113,104.00 | 16.6x | -10.1x | 9.6x |
| Mon, 19 Sep 2022 | HK$315.6b | HK$34.2b | -HK$33,501,064,041.00 | 20.7x | -9.4x | 9.2x |
| Wed, 17 Aug 2022 | HK$335.0b | HK$32.8b | -HK$46,025,407,450.00 | 12.1x | -7.3x | 10.2x |
| Fri, 15 Jul 2022 | HK$365.0b | HK$33.0b | -HK$46,533,006,363.00 | 14x | -7.8x | 11.1x |
| Sun, 12 Jun 2022 | HK$357.2b | HK$33.0b | -HK$46,592,039,317.00 | 14.7x | -7.7x | 10.8x |
| Tue, 10 May 2022 | HK$314.0b | HK$34.2b | -HK$45,397,203,424.00 | 12.8x | -6.9x | 9.2x |
| Thu, 07 Apr 2022 | HK$372.3b | HK$36.4b | -HK$46,242,884,784.00 | 14.7x | -8.1x | 10.2x |
| Sat, 05 Mar 2022 | HK$326.8b | HK$34.0b | -HK$31,239,577,575.00 | 13.7x | -10.5x | 9.6x |
| Mon, 31 Jan 2022 | HK$293.1b | HK$31.1b | -HK$31,841,442,755.00 | 11.3x | -9.2x | 9.4x |
| Wed, 29 Dec 2021 | HK$379.2b | HK$31.1b | -HK$31,826,765,471.00 | 13.2x | -11.9x | 12.2x |
| Fri, 26 Nov 2021 | HK$516.9b | HK$31.0b | -HK$31,721,285,866.00 | 13.7x | -16.3x | 16.7x |
| Sun, 24 Oct 2021 | HK$492.3b | HK$30.7b | -HK$31,774,543,189.00 | 15.3x | -15.5x | 16x |
| Tue, 21 Sep 2021 | HK$521.3b | HK$30.4b | -HK$31,436,180,691.00 | 16.5x | -16.6x | 17.1x |
| Thu, 19 Aug 2021 | HK$514.0b | HK$30.2b | -HK$32,058,827,347.35 | 15.1x | -16x | 17x |
| Thu, 03 Jun 2021 | HK$629.6b | HK$27.8b | -HK$26,637,487,691.09 | 21.6x | -23.6x | 22.7x |
| Sun, 07 Mar 2021 | HK$546.6b | HK$24.0b | -HK$26,645,675,939.75 | 66.8x | -20.5x | 22.7x |
| Wed, 09 Dec 2020 | HK$351.8b | HK$20.1b | -HK$13,901,301,810.97 | 43.2x | -25.3x | 17.5x |
| Tue, 01 Sep 2020 | HK$337.6b | HK$17.2b | -HK$11,180,934,453.59 | 52x | -30.2x | 19.7x |
| Fri, 05 Jun 2020 | HK$249.8b | HK$16.9b | -HK$10,409,928,242.87 | 30.4x | -24x | 14.7x |
| Mon, 09 Mar 2020 | HK$184.8b | HK$17.1b | -HK$7,752,252,997.18 | 35.8x | -23.8x | 10.8x |
Price to Earnings Ratio
-22.8x
Current Industry PE
- Investors are relatively neutral on the Hong Kong Biotechs industry at the moment, indicating that they anticipate long term growth rates to remain steady.
- The industry is trading close to its 3-year average PS ratio of 14.8x.
Past Earnings Growth
- The earnings for companies in the Biotechs industry have deteriorated over the last three years.
- Meanwhile revenues for these companies have grown 27% per year.
- This means that although more sales are being generated, either the cost of doing business or the level of investment back into businesses has increased, which has caused losses to expand.
Industry Trends
Which industries have driven the changes within the Hong Kong Healthcare industry?
| HK Market | 2.72% | |
| Healthcare | 1.88% | |
| Biotech | 3.43% | |
| Biotech | 3.43% | |
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.
Top Stock Gainers and Losers
Which companies have driven the market over the last 7 days?
| Company | Last Price | 7D | 1Y | Valuation | |
|---|---|---|---|---|---|
| 1801 Innovent Biologics | HK$47.00 | 9.0% +HK$6.0b | 52.8% | PS13.7x | |
| 9926 Akeso | HK$51.00 | 6.7% +HK$2.7b | 151.9% | PS142.9x | |
| 9995 RemeGen | HK$68.90 | 4.3% +HK$1.5b | 43.2% | PE116.5x | |
| 1952 Everest Medicines | HK$27.60 | 18.5% +HK$1.3b | 8.9% | PS6735.5x | |
| 2162 Keymed Biosciences | HK$69.90 | 5.9% +HK$1.1b | 177.4% | PS80.6x |